Gyre Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 6.41 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 679.68M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated l...